Related Experiment Video

Updated: Sep 6, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.9K

circRNA: Regulatory factors and potential therapeutic targets in inflammatory dermatoses

Ruifeng Liu1, Luyao Zhang2, Xincheng Zhao1

  • 1Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, China.

Journal of Cellular and Molecular Medicine
|June 30, 2022
PubMed

Insights

Circular RNAs (circRNAs) are key regulators in skin diseases. This review explores their role in inflammatory dermatoses like psoriasis and atopic dermatitis, highlighting their therapeutic potential.

Area of Science:

  • Dermatology and Molecular Biology
  • Investigates the role of circular RNAs in skin pathophysiology.

Background:

  • Skin diseases, particularly inflammatory dermatoses, impose significant burdens on patients.
  • Understanding disease pathogenesis is crucial for developing effective treatments.
  • Circular RNAs (circRNAs) are emerging as critical regulators in various diseases, including skin conditions.

Purpose of the Study:

  • To review the biogenesis, properties, and functions of circRNAs.
  • To summarize the involvement of circRNAs in the pathogenesis of inflammatory dermatoses.
  • To explore circRNAs as potential therapeutic targets for skin diseases.

Main Methods:

  • Literature review of studies on circRNAs and inflammatory dermatoses.
  • Synthesis of information on circRNA biogenesis and function.
  • Analysis of circRNA roles in specific conditions like psoriasis, lupus erythematosus, atopic dermatitis, lichen planus, and acne.

Main Results:

  • CircRNAs play diverse regulatory roles in cellular processes relevant to skin health and disease.
  • Specific circRNAs have been implicated in the pathogenesis of major inflammatory dermatoses.
  • Dysregulation of circRNAs is linked to disease severity and progression.

Conclusions:

  • CircRNAs are integral to the pathophysiology of inflammatory skin diseases.
  • Targeting circRNAs offers promising avenues for novel therapeutic strategies.
  • Further research into circRNAs could revolutionize the treatment of dermatological conditions.
Keywords:
circRNAdermatosesinflammationskin

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.2K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.7K

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
6.8K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
227
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
263